Publications by authors named "Victor A Chow"

Claim this Profile
L
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani, Victor A Chow

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Victor A Chow

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
Jennifer L Crombie, Caron A Jacobson, Robert Redd, Geoffrey Shouse, Alex F Herrera, Victor A Chow

Haematologica· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, Erin Mullane, Victor A Chow

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.
Chikara Ogimi, Elizabeth M Krantz, Jonathan L Golob, Catherine Liu, Alpana Waghmare, Victor A Chow

Bone Marrow Transplant· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Jordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, Joshua A Hill, Vicky Wu, Victor A Chow

Blood· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Victor A Chow, Ryan D Cassaday, Theodore A Gooley, Stephen D Smith, Brenda M Sandmaier

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma.
Jennifer L Crombie, Loretta J Nastoupil, Robert Redd, Kevin Tang, Geoffrey Shouse, Victor A Chow

Blood Adv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Michael Scordo, Trent P Wang, Kwang W Ahn, Yue Chen, Sairah Ahmed, Victor A Chow

JAMA Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Sherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, Brenda M Sandmaier, Leona A Holmberg, Victor A Chow

Transplant Cell Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.
Victor A Chow, Ajay K Gopal, Jordan Gauthier, Yolanda D Tseng, Cameron J Turtle

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.
Victor A Chow, Paul S Martin, Stephen D Smith, Brian G Till, Solomon A Graf

Br J Haematol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Victor A Chow, Joseph G Rajendran, Darrell R Fisher, Frederick R Appelbaum, Ryan D Cassaday

Am J Hematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Mehdi Hamadani, Manoj Khanal, Kwang W Ahn, Carlos Litovich, Victor A Chow

Biol Blood Marrow Transplant· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Where does transplant fit in the age of targeted therapies?
Victor A Chow, Ajay K Gopal

Hematology Am Soc Hematol Educ Program· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Victor A Chow, Ajay K Gopal, David G Maloney, Cameron J Turtle, Stephen D Smith

Am J Hematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited Utility of Outpatient Surveillance Blood Cultures in Hematopoietic Cell Transplant Recipients on High-Dose Steroids for Treatment of Acute Graft-versus-Host-Disease.
Erica Stohs, Victor A Chow, Catherine Liu, Lori Bourassa, Arianna Miles-Jay

Biol Blood Marrow Transplant· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
Stephen D Smith, Prathima Reddy, Alexandra Sokolova, Victor A Chow, Ryan C Lynch

Am J Hematol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Victor A Chow, Mazyar Shadman, Ajay K Gopal

Blood· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis